Comment on 'Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab'. | Acta Oncol;60(4): 564-565, 2021 Apr. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Search Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search

Comment on 'Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab'.

Kocak, Mehmet Zahid.

Affiliation

Kocak MZ; Medical Oncology Department, Necmettin Erbakan University, Meram, Konya, Turkey.

Acta Oncol ; 60(4): 564-565, 2021 Apr.

Article in En | MEDLINE | ID: mdl-33612057

Subject(s)

Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung/drug therapy; Humans; Lung Neoplasms/drug therapy

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Humans Language: En Journal: Acta Oncol Journal subject: NEOPLASIAS Year: 2021 Type: Article Affiliation country: Turkey

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Humans Language: En Journal: Acta Oncol Journal subject: NEOPLASIAS Year: 2021 Type: Article Affiliation country: Turkey